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Abstract
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) of EFSA was
requested to deliver a scientiﬁc opinion on the implications for human health of the ﬂavouring substance
40,5,7-trihydroxyﬂavanone or naringenin [FL-no: 16.132], in the Flavouring Group Evaluation 410
(FGE.410), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council.
The substance occurs naturally in grapefruits, oranges and tomatoes. It is intended to be used as a
ﬂavouring substance with ﬂavour-modifying properties in speciﬁc categories of food. Information on
speciﬁcations and manufacturing of [FL-no: 16.132] were considered adequate; however, data on
stability in food are incomplete. The Panel noted that the available genotoxicity studies have signiﬁcant
shortcomings and are insufﬁcient to conclude on the genotoxic potential of naringenin. Therefore,
[FL-no: 16.132] cannot be evaluated through the Procedure. Additionally, the Panel noted that inhibition
of CYP 450 by [FL-no: 16.132] has been clearly demonstrated in animal species in vivo which implies that
the substance may interact with the metabolism and elimination of medicines and no convincing
information is available that this does not pose a risk to humans at the estimated levels of exposure. To
continue with the safety assessment of [FL-no: 16.132], a bacterial gene mutation assay and an in vitro
micronucleus assay (according to OECD guidelines 471, 487 and GLP) are required. Even if these studies
do not indicate a genotoxic potential, additional toxicological data are needed to ﬁnalise the evaluation.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
The use of ﬂavouring in food is regulated under Regulation (EC) No 1334/20081 of the European
Parliament and Council of 16 December 2008 on ﬂavourings and certain food ingredients with the
ﬂavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for ﬂavouring substances.
Regulation (EC) No 1331/20082 establishing a common authorization procedure on food additives,
food enzymes and food ﬂavourings applies for the evaluation and approval of new ﬂavouring
substances.
An application for the substance 40,5,7-trihydroxyﬂavanone (CASrn 67604-48-2) has been submitted
to the Commission for authorisation as a new ﬂavouring substance. The application has now been
considered valid by the Commission.
1.1.1. Terms of Reference
In order for the Commission to be able to consider its inclusion of this substance in the Union list of
ﬂavourings and source materials (Annex I of Regulation (EC) No 1334/2008), EFSA should carry out a
safety assessment of this substance.
The European Commission requests the European Food Safety Authority to carry out a safety
assessment on 40,5,7-trihydroxyﬂavanone as a new ﬂavouring substance in accordance with Regulation
(EC) No 1331/2008.
1.2. Interpretation of the Terms of Reference
The present scientiﬁc opinion FGE.410 covers the safety assessment of the following ﬂavouring
substance: 40,5,7-trihydroxyﬂavanone [FL-no: 16.132], also reported as naringenin. For sake of
consistency, only the trivial name will be used in this opinion. The substance will be evaluated as a
ﬂavouring substance with modifying properties3 in line with Regulation (EC) No 1334/2008.
2. Data and methodologies
The present evaluation is based on data on naringenin [FL-no: 16.132] provided by the applicant in
a dossier submitted in support of its application for authorisation as a new ﬂavouring substance.
The estimation of the dietary intake of naringenin will be based on use and use levels submitted by
the applicant for the following categories of food and beverages: 1.7, 3.0, 5.1, 6.3, 7.2, 8.2, 12.5,
14.1c, 14.2.1 and 15.1. (see Appendix B).
The safety assessment of naringenin [FL-no: 16.132] (CASrn 67604-48-2) will be carried out by
EFSA in accordance with the procedure as lined out in the EFSA scientiﬁc opinion ‘Guidance on the
data required for the risk assessment of ﬂavourings to be used in or on foods’ (EFSA CEF Panel,
2010a) and the technical report of EFSA ‘Proposed template to be used in drafting scientiﬁc opinions
on ﬂavouring substances (explanatory notes for guidance included)’ (EFSA, 2012).
The Procedure for the safety evaluation of the ﬂavouring substance is given in Appendix A (see also
Cramer et al., 1978).
3. Assessment
3.1. Identity of the substance
40,5,7-Trihydroxyﬂavanone has been allocated the FLAVIS number [FL-no: 16.132]. The trivial name
of the ﬂavouring substance is naringenin. For the sake of consistency, this will be used in this opinion.
1 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.
2 Regulation (EC) No 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a common
authorisation procedure for food additives, food enzymes and food ﬂavourings. OJ L 354, 31.12.2008, p. 1–6.
3 https://ec.europa.eu/food/sites/food/files/safety/docs/fs_food-improvement-agents_flavourings-guidance_modifying_properties.
pdf
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3.2. Organoleptic characteristics
Naringenin has been reported as an odourless off-white to light yellow powder with sweet to sour
taste. Its taste, however, has not been reported to be signiﬁcant as can be seen from the sensory data
provided on naringenin when tested as a ﬂavour modiﬁer in beverages, dairy drinks, yoghurt, soft
candy, cereals, ﬂavoured snacks, soups and broths.
3.3. Existing authorisations and evaluations
The Panel is not aware of any ofﬁcial evaluations of FGE.410 performed by national or international
authorities. In August 2015, [FL-no: 16.132] was allocated the status ‘Generally recognised as safe’
(GRAS) by the Flavour and Extract Manufactures Associations (FEMAs) expert Panel (FEMA no 4797);
therefore, naringenin [FL-no: 16.132] was included in the FEMA GRAS 27 list.
3.4. Technical data
The speciﬁcations of the ﬂavouring substance are summarised in Table 1.
3.4.1. Information on the conﬁguration of the ﬂavouring substance
Naringenin obtained via extraction and subsequent hydrolysis from grapefruits, is a mixture of 2R-
and 2S isomers that is variable in isomeric composition (Gafﬁeld et al., 1975).
3.4.2. Manufacturing process
The source material for the manufacturing process of naringenin is grapefruit peel (Citrus maxima
(J. Burman) Merr.).
The glycoside (naringin) of [FL-no: 16.132] is ﬁrst extracted from grapefruit peel with 50% ethanol
in water to obtain substances of midpolarity such as ﬂavonoids. The ﬂuid extract is then centrifuged to
remove particles and washed through a resin column. The ﬂavonoids are released from the resin using
65% ethanol in water. The collected ethanol fractions are then concentrated to partially remove
ethanol and water. Subsequently, this concentrate is spray-dried and the glycoside is crystallised.
Enzymatic or acidic hydrolysis follows during which the glycosidic bond in naringin is hydrolysed to
naringenin. Finally, naringenin is crystallised and vacuum-dried.
The applicant provided data on the presence of ethanol as a residual solvent and heavy metals in
the ﬁnal product.
Although there are no regulatory restrictions for contaminants in ﬂavourings, the Panel took into
consideration the provisions of Commission Regulation (EU) No 231/20124 laying down speciﬁcations
for food additives listed in Annexes II and III to Regulation (EC) No 1333/20085 of the European
Parliament and of the Council. When ethanol is used in the manufacturing of certain food additives
(e.g. food colours, gums, sweeteners, etc.), different restrictions on the levels of ethanol per food
additive are reported in the Regulation (e.g. from 50 mg/kg to 2% of ethanol in the food additive).
The level of 5,000 mg ethanol reported per kg of naringenin [FL-no: 16.132] is within the occurrence
range of ethanol in food additives. Similarly, the concentrations of arsenic, lead, cadmium and mercury
reported for naringenin, comply with the requested speciﬁcations of food additives.
3.4.3. Stability and decomposition products
The stability of naringenin [FL-no: 16.132] was evaluated over a 5-week period at room
temperature and at 40°C. The substance was found to be stable at both temperatures (recovery
≥ 94%). However, no tests were conducted for the substance at temperatures higher than 40°C, even
though the substance is intended to be incorporated in food categories 6.3 (breakfast cereals) and 7.2
(ﬁne bakery wares) where higher process temperatures may apply.
Although the ﬂavouring substance is also intended to be used in beverages, the applicant did not
investigate the stability of the ﬂavouring substance in solution. The Panel conducted a literature search
4 Regulation (EU) No 231/2012 of 9 March 2012 laying down speciﬁcations for food additives listed in Annexes II and III to
Regulation (EC) No 1333/2008 of the European Parliament and of the Council. OJ L 83, 22.3.2012, p. 1–295.
5 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. OJ L
354, 31.12.2008, p. 16–33.
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on this topic and concluded that the substance would not be expected to be unstable in solution,
based on Biesaga (2011).
Interaction with food components
No information given.
3.4.4. Particle size6
The particle size of the commercial material was reported to be smaller than 80 mesh (~ 0.18 mm)
(Flavour Industry, 2015). No particle size distribution for the ﬁnal product was provided. Based on the
reported manufacturing process and the available information on solubility, consumer exposure is not
anticipated to be in form of nanoparticles.
3.4.5. Conclusion on speciﬁcations
The Panel concluded that the speciﬁcations and manufacturing data provided for the ﬂavouring
substance are adequate. Data on stability in food are incomplete, since the heating and storage
conditions for which stability in food was investigated, were not representative for all intended uses.
3.5. Structural/metabolic similarity to substances in an existing FGE
3.5.1. Naringenin/naringin
In the technical dossier, the applicant applies the read-across between naringenin [FL-no: 16.132]
and naringin [FL-no: 16.058], a related ﬂavouring substance evaluated in FGE.32 (EFSA CEF Panel,
2010b). Based on this approach, no new toxicity studies were conducted on naringenin.
To investigate the validity of the read-across and the relevance of a group-based evaluation of the
ﬂavouring substance according to the EFSA Guidance (EFSA CEF Panel, 2010a), the Panel took the
structural/metabolic similarities between naringenin [FL-no: 16.132] and the substances from FGE.32
into consideration.
Naringenin (aglycone) and naringin (glycoside) (see Table 2) share as a common part the ﬂavanone
structure. However, the absence of the rhamnose-glucose moiety at the 7-position of naringenin results
in major differences in absorption and bioavailability after oral exposure between the two compounds.
The most important of these differences is linked to the different sites of absorption of the two
substances. Brieﬂy, naringin has to be metabolised to naringenin by hydrolases in the colon before it
can be absorbed (as naringenin) (see Figure 1). However, when naringenin is administered orally as
such, it will be rapidly absorbed from the small intestine. This is also supported by similar results of the
glycoside/aglycone ﬂavanone pair hesperidin/hesperetin where the same rhamnose-glucose moiety is
involved (see Appendix C for more details). This difference in absorption results in major differences in
pharmacokinetics between naringin and naringenin. Moreover, the difference in absorption site may
affect extent and pattern of metabolism by the gut microﬂora (see Section 3.8). Based on the above,
the Panel concluded that despite the common ﬂavanone moiety and the common metabolites of the
two substances identiﬁed in urine, the read-across between naringenin and naringin is not applicable.
Figure 1: The metabolic conversion of naringin to naringenin in the colon
6 Commission Recommendation 2011/696/EU of 18 October 2011 on the deﬁnition of nano-materials. Ofﬁcial Journal of the
European Union L257/38-40 on 20.10.2010 (http://ec.europa.eu/environment/chemicals/nanotech/pdf/commission_recomme
ndation.pdf).
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Table 1: Speciﬁcations
FL-no Chemical name
Structural
formula
JECFA no
FEMA no
CoE no
CAS no
EINECS no
Odour
Phys. form
Mol.
formula
Mol.
weight
Impurities
Solubility(a)
Solubility in
ethanol(b)
Others
Boiling
point, °C(c)
Melting
point, °C
ID test
Assay
minimum
Refrac.
index(d)
Spec.
gravity(e)
Speciﬁcation
comments
16.132 40,5,7-Trihydroxyﬂavanone
O
OOH
OH
OH 4797
–
–
67604-48-2
–
Odourless
off-white
to light
yellow
powder with
sweet to
sour taste
Solid
C15H12O5
272.257
Ethanol ~ 1% Poorly soluble(f)
Soluble
–
–
251
NMR
> 95%
n.a.
n.a.
Trivial name:
naringenin
The CASrn refers
to the racemate
(Flavour Industry,
2017)
FL-No: FLAVIS number; JECFA: The Joint FAO/WHO Expert Committee on Food Additives; FEMA: Flavor and Extract Manufacturers Association; CoE: Council of Europe; CAS: Chemical Abstract
Service; EINECS: European Inventory of Existing Commercial Chemical Substances; ID: Identity; NMR: nuclear magnetic resonance spectroscopy.
(a): Solubility in water, if not otherwise stated.
(b): Solubility in 95% ethanol, if not otherwise stated.
(c): At 1,013.25 hPa (1 atm), if not otherwise stated.
(d): At 20°C, if not otherwise stated.
(e): At 25°C, if not otherwise stated.
(f): Range from 9 to 475 mg/L (Shulman et al., 2011; Tomassini et al., 2004; ChemIDPlus-A Toxnet Database at https://chem.nlm.nih.gov/chemidplus/rn/480-41-1).
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3.5.2. Naringenin/quercetin
Following a request for genotoxicity data on naringenin, the applicant did not proceed with the
studies requested but applied a read-across between naringenin [FL-no: 16.132] and the ﬂavonol
quercetin (see Table 2) for which some genotoxicity data are available.
To investigate the validity of the read-across to quercetin and the relevance of a group-based
evaluation of the ﬂavouring substance according to the EFSA Guidance (EFSA CEF Panel, 2010a), the
Panel took the structural/metabolic similarities between naringenin [FL-no: 16.132] and quercetin into
consideration. Regarding the structural similarity between the two substances, the Panel noted that
naringenin is a ﬂavanone, whereas quercetin is a ﬂavonol with a double bond in position 2 and a
hydroxyl group in position 3 that is subject to tautomerism. Moreover, the two hydroxyl groups on the
C-ring of quercetin are subject to oxidation and may yield reactive quinones, highly reactive
electrophiles capable of reacting with thiols. This illustrates that these two substances may follow
different metabolic pathways.
Additionally, the Panel noted that there is variability in the toxicological proﬁles between the two
substances: naringenin was found to be non-mutagenic in bacteria when tested in S. Typhimurium
strains TA98, TA100, TA1535, TA1537 and TA1538 (+/ S9) (see Section 3.7), whereas quercetin was
found to be mutagenic in strains TA98 and TA100 (NTP, 1992).
Based on the above, the Panel concluded that the read-across between naringenin and quercetin is
not applicable.
3.5.3. Conclusion on structural/metabolic similarity
Considering the above, the Panel concluded that the read-across between naringenin and naringin
and quercetin is not applicable (Table 2). Consequently, naringenin [FL-no: 16.132] will be evaluated
as a stand-alone substance.
3.6. Exposure assessment (details are reported in Appendix B)
All data necessary for the calculation of normal and maximum occurrence levels for reﬁned
subcategories of foods and beverages are reported in Appendix B.
3.6.1. Natural occurrence in foods
Like its glycoside naringin, naringenin is present in grapefruit. Its concentration in grapefruit juice
ranges from 0 to 12.6 mg/100 mL (Zhang, 2007). Both ﬂavonoids also occur in tomatoes (Bugianesi
et al., 2002), and in oranges (Kumpulainen et al., 1999; Erlund, 2004; e Silva et al., 2014) (Table 3).
Table 2: Naringenin and substances considered for structural/metabolic similarity
FGE FL-no Name Structural formula
410 16.132 Naringenin
O
OOH
OH
OH
32 16.058 Naringin
Quercetin
O
OOH
OH
OH
OH
OH
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3.6.2. Non-food sources of exposure
According to the applicant, naringenin is not used in fragrances. There is no known non-food
source of exposure to humans.
3.6.3. Chronic dietary exposure
The exposure assessment to be used in the Procedure for the safety evaluation of naringenin is the
chronic added portions exposure technique (APET) estimate (EFSA CEF Panel, 2010a). The chronic
APET for [FL-no: 16.132] has been calculated for adults and children (see Table 4), and these values,
expressed per kg body weight (bw), will be used in the Procedure (see Appendix B). The chronic APET
calculation is based on the combined normal occurrence level and the standard portion size (see
Appendix B). Exposure from other dietary sources is strictly related to naringenin per se.
3.6.4. Acute dietary exposure (Table 5)
The acute APET calculation for [FL-no: 16.132] is based on the combined maximum occurrence
level and large portion size i.e. three times standard portion size (see Appendix B).
Table 3: Natural occurrence of naringin, naringenin in foods
FL-no Name Food source Amount
16.132 Naringenin Tomato, grapefruit,
oranges
8–42 mg/kg tomato(a), 0–12.6 mg/100 mL
in grapefruit juice(b), 0.01–0.36 mg/100 mL
in orange juice(c)
16.058 Naringin Grapefruit, oranges, tomato
skin(d), tomato paste(d)
10–86 mg/100 mL grapefruit juice(b),
0.01–0.3 mg/100 mL in orange juice(c)
(a): Bugianesi et al. (2002).
(b): Zhang (2007).
(c): e Silva et al. (2014).
(d): No quantitative information found for naringin in the cited reference (Bugianesi et al., 2002).
Table 4: APET – chronic dietary exposure
Chronic APET
Added as ﬂavouring
substance(a)
Other dietary sources(b),(f) Combined(c)
lg/kg bw
per day
lg/person
per day
lg/kg bw
per day
lg/person
per day
lg/kg bw
per day
lg/person
per day
Adults(d) 170 10,000 27 1,600 194 11,600
Children(e) 420 6,300 67 1,008 487 7,308
APET: added portions exposure technique; bw: body weight; n.a. not applicable: the acute APET calculation is based on the
combined maximum occurrence level.
(a): APET Added is calculated on the basis of the normal amount of ﬂavouring added to a speciﬁc food category.
(b): APET Other dietary sources is calculated based on the natural occurrence of the ﬂavouring in a speciﬁed food category.
(c): APET Combined is calculated based on the combined amount of added ﬂavouring and naturally occurring ﬂavouring in a
speciﬁed food category.
(d): For the adult, APET, calculation a 60-kg person is considered representative.
(e): For the child APET, calculation a 3-year-old child with a 15 kg bw is considered representative.
(f): Other dietary sources refer to naringenin as such.
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3.7. Genotoxicity (see also Appendix D)
3.7.1. Genotoxicity in vitro
Bacterial reverse mutation assay
Naringenin was tested in the Ames assay with S. Typhimurium tester strains TA98, TA100, TA1535,
TA1537 and TA1538 at concentrations ranging from 33 to 10,000 lg/plate both in the absence and
presence of S9 metabolic activation. The results obtained for mutagenicity indicated that the test
compound did not increase the number of His+ revertants both in the absence and presence of S9
metabolic activation (see Table D.1). Data were obtained from the Chemical Carcinogenesis Research
Information System (CCRIS), a database of the National Library of Medicine’s TOXNET system
(Reference included as Ames Study results).
Naringenin was also shown to have no mutagenic activity when tested in S. Typhimurium tester
strains TA100 and TA98 using the pre-incubation method with or without metabolic activation
(Sugimura et al., 1977; Nagao et al., 1981) and in S. Typhimurium tester strains TA1535, TA100,
TA1537, TA1538 and TA98 using both the pre-incubation and plate test methods with or without
metabolic activation (Brown and Dietrich, 1979).
Overall, the Panel noted that there are limitations due to the absence of data on S. Typhimurium
TA102 or Escherichia coli WP2 tester strains as recommended by the OECD Guideline no. 471.
Micronucleus assay
Chinese hamster V79 cells were used to evaluate DNA intercalation, metal reactivity, reactive
oxygen species (ROS) generation, functional DNA topo II interactions and clastogenicity using
modiﬁcations to the Chinese hamster V79 in vitro micronucleus assay of different bioﬂavonoids
including naringenin. The details of the micronucleus test are given below.
Chinese hamster V79 cells were treated with naringenin for three hours in the absence of S9
metabolic activation. The authors concluded that naringenin was non-clastogenic in this assay (Snyder
and Gillies, 2002). However, the Panel noted that the study was designed for research purposes and
shows signiﬁcant shortcomings that include the use of a short treatment (only 3 h), treatment in the
presence of S9 metabolic activation was not performed and the number of binucleated cells scored for
induction of micronuclei was very low (300–500 binucleated cells). The outcome of the study cannot
be considered reliable on this basis, and conclusions drawn by the authors do not appear to be
supported by convincing experimental evidence.
In response to a request for additional genotoxicity studies for naringenin, the applicant submitted
studies on the ﬂavonol quercetin which, for reasons detailed in Section 3.5 were not considered
relevant and were not taken into account in this evaluation.
Similarly, an in vivo chromosomal aberration study on naringin (Jagetia et al., 2003) was not
considered for the evaluation of naringenin [FL-no: 16.132].
Table 5: APET – acute Dietary Exposure
Acute APET
Added as ﬂavouring
substance (a)
Other dietary sources(b) Combined(c)
lg/kg bw
per day
lg/person
per day
lg/kg bw
per day
lg/person
per day
lg/kg bw
per day
lg/person
per day
Adults(d) 1,875 112,500 0 0 1,875 112,500
Children(e) 4,725 70,875 0 0 4,725 70,875
APET: added portions exposure technique; bw: body weight; n.a. not applicable: the acute APET calculation is based on the
combined maximum occurrence level.
(a): APET Added is calculated on the basis of the maximum amount of ﬂavouring added to a speciﬁc food category.
(b): APET Other dietary sources is calculated based on the natural occurrence of the ﬂavouring in a speciﬁed food category.
(c): APET Combined is calculated based on the combined amount of added ﬂavouring and naturally occurring ﬂavouring in a
speciﬁed food category.
(d): For the adult APET, calculation a 60-kg person is considered representative.
(e): For the child APET, calculation a 3-year-old child with a 15 kg bw is considered representative.
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3.7.2. Conclusion on genotoxicity assessment
Overall, the Panel concluded that the available data set is insufﬁcient to conclude on the genotoxic
potential of naringenin. A bacterial gene mutation assay and an in vitro micronucleus assay (according
to OECD guidelines 471, 487 and GLP) (OECD, 1997 and 2014) are required for [FL-no: 16.132].
3.8. Absorption, distribution, metabolism and elimination (Appendix C)
Naringenin is rapidly absorbed following oral administration and is subject to phase II metabolic
reactions (primarily conjugation with glucuronic acid and/or sulfate). This is followed by excretion of
the conjugates via bile and urine. Naringenin that is not absorbed within the upper part of the
gastrointestinal (GI) tract passes into the colon, where it is subject to microbial metabolism to phenolic
acids such as p-hydroxyphenylpropionic acid, p-coumaric acid and p-hydroxybenzoic acid. The
metabolic fate of a major part of the dose in humans is unknown.
Studies pertaining to the metabolic fate of naringenin are summarised in detail in Appendix C.
Naringenin cannot be assumed to be metabolised into innocuous products since in humans most of
the dose is unaccounted for in terms of metabolites.
3.9. Toxicity data
No toxicity studies were submitted for naringenin [FL-no: 16.132].
3.10. Naringenin and estrogenic activity
Studies on the oestrogenic effects of naringenin were already considered by the Panel in FGE.32
(EFSA CEF Panel, 2010b), where the Panel concluded that: ‘naringenin is a weak estrogen compared
with e.g. the phytoestrogens genistein and 8-prenylnaringenin, although its potential estrogenic effects
are controversial’.
In uterotrophic assays (Breinholt et al., 1999, 2004), indications for oestrogenic activity were
obtained at dose levels that approach the APET (11.6 mg/adult per day).
The Panel is aware that more recent studies on this topic are available. Considering all the data
gaps in the available information and the fact that consequently this evaluation cannot be ﬁnalised, the
Panel decided not to go into this aspect in depth in this opinion.
3.11. Naringenin and drug interaction
Naringenin is an inhibitor of several CYP 450 species and may interact with the metabolic
elimination of medicines. Such interactions have already been demonstrated in several in vitro and
in vivo studies in animals. Potential interaction of naringenin with medicines have been listed in the
DRUGBANK database (https://www.drugbank.ca/).
Naringenin dose-dependently increased the bioavailability of felodipine 10 mg/kg bw approx. twofold
when administered orally to Wistar rats in doses from 25 to 100 mg/kg bw for 15 consecutive days
(Sandeep et al., 2014). When rats were treated orally with naringenin at doses of 12.5 and 25 mg/kg
bw for 15 consecutive days (Pingili et al., 2016), the bioavailability of rasagiline mesylate (2 mg/kg)
was increased: its area-under-the-curve (AUC) increased from 60 to 138 ng.h/mL (with 12.5 mg
naringenin/kg) and to 232 ng.h/mL (with 25 mg naringenin/kg). At 25 mg/kg naringenin, also the
rasagiline concentration in the brain of the rats was signiﬁcantly increased. The Panel noted that there
is no adequate margin of safety between the chronic combined APET for naringenin (11.6 mg/adult per
day) and the dose levels of 12.5–100 mg/kg bw that were administered in the above in vivo studies.
Narenginin inhibited the metabolism of simvastatin in rat and human hepatocytes and microsomes
(Ki 5–30 lM; Ubeaud et al., 1999), and various cytochrome P450 isoforms with IC50 values below
5 lM (Lu et al., 2011). The CYP3A-dependent metabolism of 7-benzyloxy-4-triﬂuoromethylcoumarin
was inhibited in human (Ki = 24.6 lM), pig (Ki = 15.6 lM) and mouse (Ki = 19.6 lM) microsomes
(Burkina et al., 2016); the glycoside naringin had no inhibitory effect in this system. Moreover, the
substance suppressed CYP1B1 transactivation in vitro at 5 lM (Poon et al., 2013).
Considering the above, the applicant was asked to convincingly demonstrate that the substance
does not present any risk of drug interactions in its estimated levels of intake based on the APET
approach.
In their reply, the applicant referred to the Panel conclusion in FGE.32 according to which ‘the
potential for drug interactions from the intakes of the candidate ﬂavanones based on the MSDI
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approach does not give rise to concern’ (EFSA CEF Panel, 2010b). However, the Maximised Survey-
derived Daily Intake (MSDI) does no longer apply for the estimation of the exposure to ﬂavouring
substances falling within the remit of Regulation (EC) No 1331/2008 of the European Parliament and
of the Council establishing a common authorisation procedure for food additives, food enzymes and
food ﬂavourings.
The Panel concluded that in the light of currently applicable exposure (APET) estimates for
naringenin, the opinion for naringin in FGE.32 cannot be used to support the evaluation of naringenin.
This is also supported by the differences between the toxicokinetics of naringenin and naringin (see
section 3.5.1 and Appendix C).
3.11.1. Conclusion on drug interaction
The Panel noted that the applicant did not provide appropriate information to convincingly
demonstrate that there is no risk of drug interactions with [FL-no: 16.132] in humans at its estimated
levels of exposure based on the APET.
Therefore, it remains to be established whether exposure to naringenin at the level of the APET is
devoid of such interactions with drug metabolism.
3.12. Procedure for the safety assessment
The Procedure and its principles are reported in Appendix A.
Procedure steps for long-term exposure
Does naringenin give rise to concern with respect to genotoxicity?
The Panel requested additional data on the candidate substance. Since this data did not become
available and the available data is insufﬁcient to conclude on the genotoxic potential of naringenin, the
substance cannot be evaluated through the Procedure (Appendix A).
4. Conclusions
40,5,7-Trihydroxyﬂavanone or naringenin [FL-no: 16.132] evaluated in this FGE is a ﬂavanone.
Several other ﬂavanones or related substances have been evaluated in FGE.32. The Panel investigated
the possibility to use a group-based evaluation for naringenin, applying read-across. However, major
differences have been identiﬁed in bioavailability and elimination between naringenin and naringin in
FGE.32. In addition, there are also differences in the presence or absence of functional groups that will
result in differences in their toxicological proﬁles. Therefore, the Panel concluded that the application
of a group approach, including read-across is not justiﬁed. Consequently, the Panel decided to conduct
an individual evaluation for naringenin.
Speciﬁcations and manufacturing process
Speciﬁcations including complete purity criteria and identity for the material of commerce for [FL-no:
16.132] have been provided.
The information provided on the manufacturing process was considered adequate by the Panel.
Data on stability in food are incomplete, since the heating and storage conditions for which stability in
food was investigated, were not representative for all intended uses.
Use and exposure
Naringenin [FL-no: 16.132] is intended to be used as a ﬂavouring substance with ﬂavouring
modifying properties3 in a variety of foods. In addition, naringenin [FL-no: 16.132] occurs in grapefruit,
mainly in the form of its glycoside (naringin) but also as such. It can be also naturally found in
tomatoes and oranges.
The chronic combined dietary exposure to naringenin has been estimated at 11,600 lg/person per
day (194 lg/kg bw per day) for a 60-kg adult and 7,308 lg/person per day (487 lg/kg bw per day)
for a 15-kg 3-year-old child. The Panel notes that ~ 84% of the chronic combined exposure estimate
would originate from the use of naringenin as ﬂavouring substance.
The highest acute intake of naringenin (as added ﬂavouring substance) results from the consumption
of dairy-based desserts (e.g. pudding, fruit or ﬂavoured yoghurt) containing 300 mg/kg of naringenin
consumed by a 60-kg adult or a 15-kg 3-year-old child. This results in an intake of 112.5 mg/person per
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day (1,875 lg/kg bw per day) for a 60-kg adult and an intake of 70.9 mg/person per day (4,725 lg/kg
bw per day) for a 15-kg 3-year-old child.
Absorption, distribution, metabolism and elimination
Absorption, distribution, metabolism and elimination (ADME) studies with [FL-no: 16.132] in rats
and humans indicate that naringenin is rapidly absorbed after oral administration; it is converted to
conjugates and also metabolised in the GI tract. In humans, most of the dose is unaccounted for in
terms of metabolites.
Genotoxicity
The Panel noted that the available genotoxicity studies have signiﬁcant shortcomings. A bacterial
gene mutation assay and an in vitro micronucleus assay (according to OECD guidelines 471, 487 and
GLP) are required for [FL-no: 16.132].
Consequently, the substance cannot be evaluated through the Procedure.
Toxicity
The applicant did not provide subchronic or chronic toxicity studies on naringenin.
Oestrogenic activity
Naringenin has been reported to exhibit weak oestrogenic activity. The Panel, considered that the
current evaluation of naringenin cannot be ﬁnalised and decided not to go into this aspect in depth.
Interaction with drugs
The Panel noted that inhibition of CYP 450 species by [FL-no: 16.132] has been clearly
demonstrated in animal species in vivo which implies that the substance may interact with the
metabolism and elimination of medicines. For this, it needs to be convincingly demonstrated that there
is no risk of drug interactions resulting from exposure to [FL-no: 16.132] in humans at its estimated
levels of exposure.
Conclusion
Overall, the Panel cannot reach a conclusion as to the safety of naringenin [FL-no: 16.132] since
the available data on genotoxicity are not adequate. Depending on the outcome of the assessment on
genotoxicity more toxicological data are needed to ﬁnalise the evaluation.
Documentation provided to EFSA
1) Flavour Industry, 2015. Technical dossier of one new ﬂavouring substance, 40,5,7-trihydroxyﬂavanone.
2) Flavour Industry, 2017. Technical dossier of one new ﬂavouring substance, 40,5,7-trihydroxyﬂavanone,
updated in February 2017.
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Abbreviations
ADME absorption, distribution, metabolism and elimination
APET added portions exposure technique
BW body weight
CAS Chemical Abstract Service
CCRIS Chemical Carcinogenesis Research Information System
CEF EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CoE Council of Europe
EFFA European Flavour Association
EINECS European Inventory of Existing Commercial Chemical Substances
FAO Food and Agriculture Organization of the United Nations
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FLAVIS Flavour Information System database
GI gastrointestinal
GLP Good Laboratory Practice
GRAS Generally recognised as safe
HPLC HIGH-performance liquid chromatography
IC50 half maximal inhibitory concentration
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ID Identity
JECFA The Joint FAO/WHO Expert Committee on Food Additives
LC liquid chromatography
MS mass spectrometry
MRT mean residence time
MSDI Maximised Survey-derived Daily Intake
NMR nuclear magnetic resonance spectroscopy
NOAEL no observed adverse effect level
OECD Organisation for Economic Co-operation and Development
ROS reactive oxygen species
SCF Scientiﬁc Committee on Food
SPET single portion exposure technique
WHO World Health Organisation
Flavouring Group Evaluation 410
www.efsa.europa.eu/efsajournal 16 EFSA Journal 2017;15(11):5011
Appendix A – Procedure for evaluation of a new ﬂavouring substance
Figure A.1: The stepwise procedure for evaluation of new ﬂavouring substances according to Commission Regulation (EC) No 1334/2008
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Appendix B – Use levels and exposure calculations
Table B.1: Normal and maximum occurrence levels for reﬁned categories of foods and beverages
Food categories(a)
Standard
portions(b) (g)
Occurrence level as
added ﬂavouring
substance (mg/kg)
Occurrence level from
other sources(c) (mg/kg)
Combined occurrence
level from all
sources(e) (mg/kg)
Normal Maximum Average(d) Maximum Normal Maximum
01.1 Milk- and dairy-based drinks 200
01.2 Fermented and renneted milk products (plain),
excluding food category 01.1.2
(dairy-based drinks)
200
01.3 Condensed milk and analogues (plain) 70
01.4 Cream (plain) and the like 15
01.5 Milk powder and cream powder and powder
analogues (plain)
30
01.6 Cheese and analogues 40
01.7 Dairy-based desserts (e.g. pudding, fruit or
ﬂavoured yoghurt)
125 30 300 30 300
01.8 Whey and whey products, excluding whey cheeses 200
02.1 Fats and oils essentially free from water 15
02.2 Fat emulsions mainly of type water-in-oil 15
02.3 Fat emulsions mainly of type water-in-oil,
including mixed and/or ﬂavoured products
based on fat emulsions
15
02.4 Fat-based desserts excluding dairy-based
dessert products of category 1.7
50
03.0 Edible ices, including sherbet and sorbet 50 20 100 20 100
04.1.1 Fresh fruit 140 8 42
04.1.2 Processed fruit 125 8 42
04.1.2.5 Jams, jellies, marmalades 30
04.2.1 Fresh vegetables (including mushrooms and
fungi, roots and tubers, pulses and legumes,
and aloe vera), seaweed, and nut and seed
200
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Food categories(a)
Standard
portions(b) (g)
Occurrence level as
added ﬂavouring
substance (mg/kg)
Occurrence level from
other sources(c) (mg/kg)
Combined occurrence
level from all
sources(e) (mg/kg)
Normal Maximum Average(d) Maximum Normal Maximum
04.2.2 Processed vegetables (including mushrooms
and fungi, roots and tubers, pulses and
legumes, and aloe vera), seaweed, and nut
and seed purees and spreads (e.g. peanut butter)
and nuts and seeds
200
04.2.2.5 Vegetables (including mushrooms and fungi, roots
and tubers, pulses and legumes, and aloe vera),
seaweed, and nut and seed purees and spreads
(e.g. peanut butter)
30
05.1 Cocoa products and chocolate products, including
imitations and chocolate substitutes
40 30 100 30 100
05.1.3 Cocoa-based spreads, including ﬁllings 30
05.2 Confectionery, including hard and soft candy,
nougats, etc., other than 05.1, 05.3 and 05.4
30
05.3 Chewing gum 3
05.4 Decorations (e.g. for ﬁne bakery wares),
toppings (non-fruit) and sweet sauces
35
06.1 Whole, broken or ﬂaked grain, including rice 200
06.2 Flours and starches (including soya bean powder) 30
06.3 Breakfast cereals, including rolled oats 30 30 100 30 100
06.4 Pastas and noodles and like products
(e.g. rice paper, rice vermicelli, soya bean
pastas and noodles)
200
06.5 Cereal and starch based desserts (e.g. rice
pudding, tapioca pudding)
200
06.6 Batters (e.g. for breading or batters
for ﬁsh or poultry)
30
06.7 Pre-cooked or processed rice products, including
rice cakes (Oriental type only)
200
06.8 Soya bean products (excluding soya bean
products of food category 12.9 and fermented
soya bean products of food category 12.10)
100
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Food categories(a)
Standard
portions(b) (g)
Occurrence level as
added ﬂavouring
substance (mg/kg)
Occurrence level from
other sources(c) (mg/kg)
Combined occurrence
level from all
sources(e) (mg/kg)
Normal Maximum Average(d) Maximum Normal Maximum
07.1 Bread and ordinary bakery wares 50
07.2 Fine bakery wares (sweet, salty, savoury)
and mixes
80 30 200 30 200
08.1 Fresh meat, poultry and game 200
08.2 Processed meat, poultry and game products in
whole pieces or cuts
100 20 50 20 50
08.3 Processed comminute meat, poultry and
game products
100
08.4 Edible casings (e.g. sausage casings) 1
09.1.1 Fresh ﬁsh 200
09.1.2 Fresh molluscs, crustaceans and echinoderms 200
09.2 Processed ﬁsh and ﬁsh products, including molluscs,
crustaceans and echinoderms
100
09.3 Semi-preserved ﬁsh and ﬁsh products, including
molluscs, crustaceans and echinoderms
100
09.4 Fully preserved, including canned or fermented,
ﬁsh and ﬁsh products, including molluscs,
crustaceans and echinoderms
100
10.1 Fresh eggs 100
10.2 Egg products 100
10.3 Preserved eggs, including alkaline, salted
and canned eggs
100
10.4 Egg-based desserts (e.g. custard) 125
11.1 Reﬁned and raw sugar 10
11.2 Brown sugar excluding products of food category 11.1 10
11.3 Sugar solutions and syrups, and (partially) inverted
sugars, including molasses and treacle, excluding
products of food category 11.1.3 (soft white sugar,
soft brown sugar, glucose syrup, dried glucose
syrup, raw cane sugar)
30
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Food categories(a)
Standard
portions(b) (g)
Occurrence level as
added ﬂavouring
substance (mg/kg)
Occurrence level from
other sources(c) (mg/kg)
Combined occurrence
level from all
sources(e) (mg/kg)
Normal Maximum Average(d) Maximum Normal Maximum
11.4 Other sugars and syrups (e.g. xylose, maple
syrup, sugar toppings)
30
11.5 Honey 15
11.6 Table-top sweeteners, including those containing
high-intensity sweeteners
1
12.1 Salt and salt substitutes 1
12.10 Protein products other than from soybeans 15
12.2 Herbs, spices, seasonings and condiments (e.g.
seasoning for instant noodles)
1
12.3 Vinegars 15
12.4 Mustards 15
12.5 Soups and broths 200 20 50 8 42 28 92
12.6 Sauces and like products 30
12.7.a Salads 120 g (e.g. macaroni salad, potato salad)
excluding cocoa- and nut-based spreads
of food categories
120
12.7.b Sandwich spreads (20 g), excluding cocoa- and
nut-based spreads of food categories
20
12.8 Yeast and like products 1
12.9 Soybean-based seasonings and condiments 15
12.9.1 Fermented soya bean products (e.g. miso) 40
12.9.2 Soybean sauce 15
12.9.3 Fermented soybean sauce 15
13.2.a Complementary foods for infants and young
children: Dry instant cereals (with or without milk),
including pasta
110
13.2.b Complementary foods for infants and young
children: Meat based or ﬁsh based dinner
170
13.2.c Complementary foods for infants and young
children: Dairy based dessert
110
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Food categories(a)
Standard
portions(b) (g)
Occurrence level as
added ﬂavouring
substance (mg/kg)
Occurrence level from
other sources(c) (mg/kg)
Combined occurrence
level from all
sources(e) (mg/kg)
Normal Maximum Average(d) Maximum Normal Maximum
13.2.d Complementary foods for infants and young children:
Vegetables, potatoes, broth, soups, pulses
170
13.2.e Complementary foods for infants and young children:
Biscuits and cookies
20
13.2.f Complementary foods for infants and young children:
Fruit puree
110
13.2.g Complementary foods for infants and young children:
Fruit juice
120
13.2.h Milk for young children 200
13.3 Dietetic foods intended for special medical purposes
(excluding food products of category 13.1 ‘Infant
formulae, follow-up formulae and other formulae for
special medical purposes for infants’)
200
13.4 Dietetic formulae for slimming purposes and
weight reduction
200
13.5 Dietetic foods (e.g. supplementary foods for
dietary use), excluding products of food categories
13.1 (Infant formulae, follow-up formulae and other
formulae for special medical purposes for infants),
13.2–13.4 and 13.6
200
13.6 Food supplements 5
14.1 Other non-alcoholic (‘soft’) beverages
(expressed as liquid)
300 20 100 20 100
14.2.1 Beer and malt beverages 300 20 100 20 100
14.2.2 Cider and perry 300
14.2.3 Grape wines 150
14.2.4 Wines (other than grape) 150
14.2.5 Mead 150
14.2.6 Distilled spirituous beverages containing
more than 15% alcohol
30
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Food categories(a)
Standard
portions(b) (g)
Occurrence level as
added ﬂavouring
substance (mg/kg)
Occurrence level from
other sources(c) (mg/kg)
Combined occurrence
level from all
sources(e) (mg/kg)
Normal Maximum Average(d) Maximum Normal Maximum
14.2.7 Aromatised alcoholic beverages (e.g. beer, wine
and spirituous cooler-type beverages, low
alcoholic refreshers)
300
15.1 Snacks, potato-, cereal-, ﬂour- or starch-based
(from roots and tubers, pulses and legumes)
30 30 500 30 500
15.2 Processed nuts, including coated nuts and nut
mixtures (with e.g. dried fruit)
30
15.3 Snacks – ﬁsh based 30
16.0 Composite foods (e.g. casseroles, meat pies,
mincemeat) – foods that could not be placed in
categories 01–15
300
(a): Most of the categories reported are the subcategories of Codex GSFA (General Standard for Food Additives) used by the JECFA in the SPET technique (FAO/WHO, 2008). In the case of
category 13.2 (complementary foods for infants and young children), further reﬁned categories have been created so that a speciﬁc assessment of dietary exposure can be performed in young
children.
(b): For Adults. In case of foods marketed as powder or as concentrates, occurrence levels must be reported for the reconstituted product, considering the instructions reported on the product
label or one of the standard dilution factors established by the JECFA (FAO/WHO, 2008):
– 1/25 for powder used to prepare water-based drinks such as coffee, containing no additional ingredients,
– 1/10 for powder used to prepare water-based drinks containing additional ingredients such as sugars (ice tea, squashes, etc.),
– 1/7 for powder used to prepare milk, soups and puddings,
– 1/3 for condensed milk.
(c): As natural constituent and/or developed during the processing and/or as carry over resulting from their use in animal feed.
(d): In order to estimate normal values in each category, only foods and beverages in which the substance is present in signiﬁcant amount will be considered (e.g. for the category ‘Fresh fruit’
04.1.1., the normal concentration will be the median concentration observed in all kinds of fruit where the ﬂavouring substance is known to occur).
(e): As added ﬂavouring or from other sources. The normal and maximum combined occurrence levels of the substance will be assessed by the applicant either by adding up occurrence levels
from added use to that from other sources or by expert judgment based on the likelihood of their concomitant presence. This will be done both for normal use levels and for maximum use
levels.
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B.1. Calculation of the Dietary Exposure – ‘Added Portions Exposure
Technique’ (APET)
Chronic Dietary Exposure7
The chronic APET calculations are based on the normal combined occurrence level by adding the
highest contributing portion of food and highest contributing portion of beverages (either among soft
drinks or alcoholic beverages). APET for children is calculated by adding the highest contributing
portion of food and highest contributing portion of beverages (among soft drinks). Furthermore, in the
APET calculation for children the portion sizes listed in Table B.1 are adjusted by a factor 0.63 to take
into account the smaller portion sizes consumed by children.
Adults
On the basis of normal occurrence level from the added ﬂavouring only
Solid food: The maximum intake will be from category 12.5 (Soups and broths) with the normal
combined occurrence level of 4,000 lg/adult per day.
Beverage: The two categories (14.1 and 14.2.1) to which naringenin is added have the same
normal combined occurrence level of 6,000 lg/adult per day.
The total APET will be 10,000 lg/adult per day corresponding to 170 lg/kg bw per day for a 60-kg
person.
Children (3-year-old child of 15 kg body weight)
Solid food: The maximum intake will be from category 12.5 (Soups and broths) with the normal
combined occurrence level of 4,000 9 0.63 = 2,520 lg/child per day.
Beverage: The maximum intake will be from category 14.1 (Non-alcoholic (‘soft’) beverages) with
the normal combined occurrence level of 6,000 9 0.63 = 3,780 lg/child per day.
The total APET will be 6,300 lg/child per day corresponding to 420 lg/kg bw per day for a 15-kg
child.
Conclusion
The higher of the two values among adults and children, expressed per kg/bw per day, should be
used as the basis for the safety evaluation of naringenin, i.e. the value of 487 lg/kg bw per day for a
15 kg child should be compared to the appropriate no observed adverse effect level (NOAEL) for
naringenin.
Combined Dietary Exposure
This is an estimate of total dietary exposure derived from both the addition of the ﬂavouring
substance to foods and beverages and other dietary sources. To estimate the APET for combined
dietary exposure, the occurrence of the substance in grapefruit and tomatoes was also taken into
account in the estimation.
Adults
Solid food: The maximum intake will be from category 12.5 (Soups and broths) with the normal
combined occurrence level of 5,600 lg/adult per day.
Beverage: The two categories (14.1 and 14.2.1) to which naringenin is added have the same
normal combined occurrence level of 6,000 lg/adult per day.
The total APET will be 11,600 lg/adult per day corresponding to 194 lg/kg bw per day for a 60-kg
person.
Children (3-year-old child of 15 kg body weight)
Solid food: The maximum intake will be from category 12.5 (Soups and broths) with the normal
combined occurrence level of 5,600 9 0.63 = 3,528 lg/child per day.
Beverage: The maximum intake will be from category 14.1 (Non-alcoholic (‘soft’) beverages) with
the normal combined occurrence level of 6,000 9 0.63 = 3,780 lg/child per day.
7 The APET has been calculated based on the occurrence levels in the food subcategories reported in the above table, with the
exclusion of categories 13.2 (complementary foods for infants and young children).
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The total APET will be 7,308 lg/child per day corresponding to 487 lg/kg bw per day for a 15-kg
child.
Acute Dietary Exposure
The calculation is based on the maximum use levels and large portion size, i.e. three times
standard portion size (see Table B.1). The APET calculation for children applies the portion sizes listed
in Table B.1 adjusted by a factor 0.63 to take into account the smaller portion sizes consumed in this
case.
Adults
The highest contribution comes from three portions of category 01.7 (Dairy-based desserts (e.g.
pudding, fruit or ﬂavoured yoghurt) and is 3 9 125 g 9 300 mg/kg = 112.5 mg/adult.
Children8
The highest contribution comes from three portions of category 01.7 (Dairy-based desserts (e.g.
pudding, fruit or ﬂavoured yoghurt)) and is 3 9 125 g 9 300 mg/kg = 112.5 9 0.63 = 70.875 mg/child.
Infants and young children (0–1 year)
Acute dietary exposure is not calculated for infants and young children.
8 Based on the same considerations as for adults but using the special factors used for chronic exposure to infants.
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Appendix C – Absorption, distribution, metabolism and elimination
40,5,7-Trihydroxyﬂavanone (naringenin) [FL-no: 16.132]
Naringenin is the aglycone of naringin, i.e. it does not have the glucose and rhamnose sugars that
are part of naringin at position 7 (see Figure C.1).
Human pharmacokinetics data: difference in pharmacokinetics between
naringin and naringenin
Some reliable human data are available on [FL-no: 16.132]. Kanaze et al. (2007) studied the
pharmacokinetics and metabolism of 95% pure racemic naringenin (and hesperitin) in six human
volunteers after a single oral dose of 135 mg in a solid dispersion capsule. Naringenin is rapidly
absorbed: already after 20 min it appeared in plasma, and reached a peak concentration of
2,010  770 ng/mL plasma (7.4 lM, determined as total naringenin, including the glucuronide and
sulfate conjugate; mean  SD in six volunteers) after 4 h. Half-life of elimination was 2.31  0.40 h.
Only 5.81  0.81% of the dose was recovered in urine during 24 h after dosing. This suggests a
major contribution of metabolism other than conjugation, such as cleavage of the C-ring in the
intestine, as discussed by the authors. They also discuss extensively the difference in pharmacokinetics
between naringenin and its precursor naringin: the latter is more slowly absorbed after hydrolysis in
the colon in humans. This was conﬁrmed by studies in the rat (Felgines et al., 2000) who fed rats with
naringin and naringenin. The appearance, plasma concentrations and urinary excretion of naringenin
conjugates after administration of naringin, were later, or lower (respectively) than after administration
of naringenin.
The rate-limiting step is the hydrolysis of the rhamnose group, which occurs only in the colon.
This has very elegantly been shown for the hesperidin/hesperitine pair by Nielsen et al. (2006) in a
cross-over trial in human volunteers. Hesperidine has exactly the same diglycoside moiety (rhamnose-
glucose) as naringin. Absorption of hesperitine is (much) more rapid when it is a glucoside (i.e. it is a
glycoside with only glucose, rather than a glycoside with rhamnose-glucose) than when it is the
naturally occurring hesperidine, containing the rhamnose-glucose (‘rutoside’) group. The reason is that
the glucoside is already rapidly hydrolysed in the small intestine, while the hydrolysis of the rutoside
(starting with the rhamnose) only takes place in the colon. When hesperitine (and by analogy
naringenin) itself will be administered, obviously no hydrolysis will be required and uptake in the small
intestine will be rapid.
Animal absorption and pharmacokinetics data
Similar rapid absorption of naringenin after oral administration was also observed in several other
species, such as rat, mice and rabbit (Hsiu et al., 2002; Ma et al., 2006; Ke et al., 2013).
Ma et al. (2006) studied pharmacokinetics of naringenin (purity over 95%) in detail in the rat.
Naringenin (purity > 95%) was administered to male and female Wistar rats (5/sex per group) at
doses of 30, 90 or 270 mg/kg bw by oral gavage following an overnight fast. They also investigated
the role of enterohepatic circulation of naringenin in bile duct-cannulated rats. The maximum plasma
concentration of free naringenin was reached within 15 min of naringenin administration (2.9, 3.7 and
4.4 ng/mL for the 30, 90 or 270 mg/kg bw groups, respectively), whereas the Cmax for total
naringenin (including the conjugates) was reached at 0.5, 2 and 2 h following administration of 30, 90
or 270 mg naringenin/kg bw, respectively (16.9, 28.0 and 43.8 ng/mL, respectively). A dose-dependent
increase in the area-under-the-curve (AUC) of free and total naringenin was observed. The elimination
half-time of total naringenin was determined to be 7.6 and 10.5 h for the 90 and 270 mg/kg bw groups,
Figure C.1: Structures of naringin and naringenin
Flavouring Group Evaluation 410
www.efsa.europa.eu/efsajournal 26 EFSA Journal 2017;15(11):5011
respectively, and the mean respective mean residence time (MRT) was 7.9 and 8.6 h. The authors noted
that the slow rate of elimination of naringenin may be attributed to glucuronidation and enterohepatic
circulation: naringenin was excreted in bile as glucuronide conjugate. Twice as much naringenin was
excreted in bile (12%) than in urine (6.25%). In comparison to control rats, the total plasma
concentration of naringenin in bile duct-cannulated rats was lower and the concentration versus time
proﬁle demonstrated no double peaks, thereby conﬁrming that naringenin undergoes enterohepatic
circulation.
Two studies were conducted to assess potential differences in the pharmacokinetics related to the
different enantiomers (R/S) of naringenin (Ya~nez et al., 2008; Wan et al., 2011). Following oral
administration, the pharmacokinetic parameters for the two enantiomers were largely similar.
Metabolism of naringenin
Metabolism of naringenin takes place primarily in the cells of the intestine walls, the liver and the
microﬂora in the colon.
Conjugation of naringenin to form sulfate and glucuronide conjugates is a major pathway in
humans. However, in the available studies most of the compound administered is unaccounted for:
recovery in urine as (un)conjugated [FL-no: 16.132] is relatively low (5–30% in 24 h). Presumably,
most of an oral dose is either excreted with the faeces and/or converted (by the colon microﬂora) to
other metabolites which remain unknown. Results of intestinal perfusions and isolated cells of rats and
mice demonstrated that it was also metabolised to apigenin (Chen et al., 2003; Orrego-Lagaron et al.,
2016). Ring cleavage by the intestinal microﬂora has been reported, resulting in metabolites such as
p-hydroxyphenylpropionic acid, p-coumaric acid and p-hydroxybenzoic acid (Felgines et al., 2000;
Donovan et al., 2006), which in fact may be major metabolites if they are also excreted with the
faeces. Felgines et al. (2000) fed a diet containing 9.2 mmol/kg feed of naringenin to rats of 170 g for
one meal, resulting in an intake of ~ 230 lmol/rat. Approx 30% was excreted as conjugated
naringenin and 10% as ring-cleaved metabolites in the next 24 h.
Further toxicokinetic data with naringenin in humans
Six healthy volunteers received orally 135 mg of each compound (hesperetin and naringenin),
under fasting conditions (Kanaze et al., 2007). Blood samples were collected at 14 different points over
a 12 h period. Urine was collected over 24 h, in ﬁve sequential time intervals. Plasma and urine
concentrations were measured using high-performance liquid chromatography (HPLC), and
pharmacokinetic parameters were calculated from these.
Naringenin was absorbed from the gastrointestinal (GI) tract and was measureable in almost all
subjects 20 mins following oral administration and reached a peak in 3.5 h. The mean peak plasma
concentration for naringenin was 2,009 ng/mL. The elimination half-life was 2.31 h. The urinary
recovery was 5.8  0.8% of the administered dose.
All six subjects successfully completed the study and were discharged in good health with no reported
undesirable or adverse effects after oral administration of the aglycone naringenin. Oral administration of
the ﬂavanone aglycones, hesperetin and naringenin, lead to their rapid absorption as their conjugated
forms. The cumulative urinary recovery data indicated low bioavailability for both ﬂavanone aglycones,
owing to extensive ﬁrst-pass metabolism partly by cleavage of the C-ring by the enzymes of intestinal
bacteria leading to degradation products such as phenolic acids (Kanaze et al., 2007).
In a second study (Erlund et al., 2001), eight healthy human volunteers were given a one-time drink
of orange or grapefruit juice at 8 mL/kg to evaluate bioavailability of naringenin. The concentration of
naringenin in the orange juice was 151 lmol/L (41 mg/L) and 1,283 lmol/L (349 mg/L) in the
grapefruit juice as determined after hydrolysis of the naringin. The orange juice therefore represents a
low dose compared with the grape fruit juice. Blood samples and urine were collected between 0 and
24 h. The resulting peak plasma concentrations of naringenin were 0.6  0.4 lmol/L from orange juice
and 6.0  5.4 lmol/L from grapefruit juice. The elimination half-life was 1.3–2.2 h, and therefore,
plasma concentrations reﬂect short-term intake. The relative urinary excretion varied depending on the
dose and was 30  25% and 1.1  0.8% for naringenin from grapefruit and orange juice, respectively.
There was a high interindividual variation in the bioavailability of the compounds as indicated by
variation in their Cmax and AUC values and this is attributed by the author to differences in GI
microﬂora.
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In a third study (Brett et al., 2009), 20 volunteers ingested orange juice and orange fruit segments
and the appearance of naringenin in plasma and urine was measured. The oranges contained 11.8 mg
naringenin (as naringin) and the orange juice contained 9.4 mg naringenin (as naringin). Plasma and
urine samples were analysed for naringenin following hydrolysis. The half-life for plasma naringenin
was 4–5 h. The percentage of naringenin excreted in the urine ranged from 6.8% to 14.5%. Low
concentrations of naringenin were detected in the plasma within 15 min of ingestion of the fruit or
juice. This study showed that there were no signiﬁcant differences in the bioavailability of naringenin
consumed in fresh fruit or in commercially processed juice. This study also conﬁrmed that
interindividual variation with respect to absorption and excretion of naringenin was indeed very high
and not related to age, sex, or BMI of the subjects.
Ameer et al. (1996) showed that naringenin is methylated at various sites after intake of naringin
by a human volunteer. Bugianesi et al. (2002) conﬁrmed that conjugated narengenin is found in
plasma after consumption of cooked tomato paste.
Conclusion on metabolism
Naringenin cannot be assumed to be metabolised into innocuous products since in humans most of
the dose is unaccounted for in terms of metabolites.
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Appendix D – Genotoxicity
Table D.1: Summary of in vitro genotoxicity studies considered by the Panel
Chemical name
[FL-no]
Test system Test object Concentration Result Reference Comments
Naringenin
[FL-no: 16.132]
Reverse mutation S. Typhimurium TA1535,
TA1537, TA1538, TA98, TA100
33–10,000
lg/plate
Negative(a) CCRIS (2014) See Section 3.7.1
Reverse mutation S. Typhimurium TA98, TA100 – Negative(a),(b) Sugimura et al. (1977),
Nagao et al. (1981)
See Section 3.7.1
Reverse mutation S. Typhimurium TA1535, TA1537,
TA1538, TA98, TA100
– Negative(a),(c) Brown and Dietrich (1979) See Section 3.7.1
Micronucleus Assay Chinese hamster V79 cells – Negative(d) Snyder and Gillies (2002) See Section 3.7.1
FL-no: FLAVIS number.
(a): With and without metabolic activation.
(b): Including pre-incubation.
(c): Including pre-incubation or plate tests.
(d): Without metabolic activation.
Flavouring Group Evaluation 410
www.efsa.europa.eu/efsajournal 29 EFSA Journal 2017;15(11):5011
